AR and prostate carcinoma: CBPD-409 also exhibited superior cytotoxicity, i.e. had the lowest IC50, when compared to other published p300/CBP degraders, bromodomain inhibitors, or HAT domain inhibitors in AR-positive prostate cancer cell lines (Figure 6B).